

Mary Linton B Peters

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7615033/publications.pdf>

Version: 2024-02-01

18
papers

279
citations

1040056

9
h-index

940533

16
g-index

19
all docs

19
docs citations

19
times ranked

521
citing authors

#	ARTICLE	IF	CITATIONS
1	Prospective study of germline genetic testing in incident cases of pancreatic adenocarcinoma. <i>Cancer</i> , 2018, 124, 3520-3527.	4.1	66
2	Organoid Sensitivity Correlates with Therapeutic Response in Patients with Pancreatic Cancer. <i>Clinical Cancer Research</i> , 2022, 28, 708-718.	7.0	38
3	Progression to pancreatic ductal adenocarcinoma from pancreatic intraepithelial neoplasia: Results of a simulation model. <i>Pancreatology</i> , 2018, 18, 928-934.	1.1	32
4	Fluoropyrimidine-Associated Cardiotoxicity: A Retrospective Case-Control Study. <i>Oncologist</i> , 2020, 25, e606-e609.	3.7	23
5	Duration and cost-effectiveness of hepatocellular carcinoma surveillance in hepatitis C patients after viral eradication. <i>Journal of Hepatology</i> , 2022, 77, 55-62.	3.7	19
6	Genetic Testing in Pancreatic Ductal Adenocarcinoma: Implications for Prevention and Treatment. <i>Clinical Therapeutics</i> , 2016, 38, 1622-1635.	2.5	18
7	Managing hereditary breast cancer risk in women with and without ovarian cancer. <i>Gynecologic Oncology</i> , 2017, 146, 205-214.	1.4	16
8	Family communication and patient distress after germline genetic testing in individuals with pancreatic ductal adenocarcinoma. <i>Cancer</i> , 2019, 125, 2488-2496.	4.1	13
9	Pancreatic cancer treatment costs, including patient liability, by phase of care and treatment modality, 2000-2013. <i>Medicine (United States)</i> , 2019, 98, e18082.	1.0	13
10	Cabozantinib in the treatment of hepatocellular carcinoma. <i>Future Oncology</i> , 2017, 13, 1915-1929.	2.4	10
11	Activity of Brigatinib in the Setting of Alectinib Resistance Mediated by ALK I1171S in ALK-Rearranged Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2019, 14, e1-e3.	1.1	8
12	Time to SARS-CoV-2 clearance among patients with cancer and COVID-19. <i>Cancer Medicine</i> , 2021, 10, 1545-1549.	2.8	6
13	Burden of illness for patients with cholangiocarcinoma in the United States: a retrospective claims analysis. <i>Journal of Gastrointestinal Oncology</i> , 2021, 12, 658-668.	1.4	5
14	Testing for Verification Bias in Reported Malignancy Risks for Side-Branch Intraductal Papillary Mucinous Neoplasms: A Simulation Modeling Approach. <i>American Journal of Roentgenology</i> , 2019, 212, 596-601.	2.2	4
15	Compound Uncommon EGFR Mutations in a Patient with Advanced NSCLC and Durable Response to Sequential EGFR Targeted Therapies. <i>Journal of Thoracic Oncology</i> , 2017, 12, e35-e36.	1.1	3
16	K Awards: The Journey of a Thousand Steps. <i>Annals of Internal Medicine</i> , 2021, , .	3.9	1
17	Genetic testing to guide screening for pancreatic ductal adenocarcinoma: Results of a microsimulation model. <i>Pancreatology</i> , 2022, 22, 760-769.	1.1	1
18	In Reply. <i>Oncologist</i> , 2020, 25, e1255-e1256.	3.7	0